Custom mRNA vaccine takes on Hard-to-Treat cancers
NCT ID NCT07182435
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tests a personalized mRNA vaccine called RH125 in 36 people with advanced solid tumors who have no standard treatment options left. The vaccine is custom-made based on each patient's tumor mutations and is given alone or with a PD-1 blocker. The main goals are to check safety, immune response, and whether the vaccine can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
personalized mRNA tumor vaccine (RH125)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard options.
What could go wrong
This is a very early Phase 1 trial with only 36 participants, so it is primarily testing safety. The vaccine may not shrink tumors or work for everyone, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
Shenzhen, Guangdong, 518100, China
Contact Phone: •••-•••-•••• Email: •••••@•••••